Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 260-269

  Calles, Antonio ^a   Kwiatkowski, Nicholas ^a,b   Cammarata, Bernard K ^a   Ercan, Dalia ^a   Gray, Nathanael S ^a,b   Jänne, Pasi A ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ARQ 197; C MET; Crizotinib; Lung cancer; Tivantinib

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; TIVANTINIB; 2 PYRROLIDONE DERIVATIVE; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; INDOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; MET PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CLONE; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; IN VITRO STUDY; LUNG CANCER CELL LINE; MICROTUBULE; MITOSIS SPINDLE; NON SMALL CELL LUNG CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; INDOLES; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; PYRROLIDINONES; QUINOLINES; SULFONES;

EID: 84920424119     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.011     Document Type: Article

References (38)

1. Adjei A.A., Schwartz B., Garmey E. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 2011, 16:788-799.
2. Basilico C., Pennacchietti S., Vigna E., Chiriaco C., Arena S., Bardelli A., Valdembri D., Serini G., Michieli P. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin. Cancer Res. 2013, 19:2381-2392.
3. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003, 22:9075-9086.
4. Brachmann S.M., Kleylein-Sohn J., Gaulis S., Kauffmann A., Blommers M.J., Kazic-Legueux M., Laborde L., Hattenberger M., Stauffer F., Vaxelaire J., Romanet V., Henry C., Murakami M., Guthy D.A., Sterker D., Bergling S., Wilson C., Brummendorf T., Fritsch C., Garcia-Echeverria C., Sellers W.R., Hofmann F., Maira S.M. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 2012, 11:1747-1757.
5. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., Riely G.J., Solomon B., Ou S.H., Kim D.W., Salgia R., Fidias P., Engelman J.A., Gandhi L., Janne P.A., Costa D.B., Shapiro G.I., Lorusso P., Ruffner K., Stephenson P., Tang Y., Wilner K., Clark J.W., Shaw A.T. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
6. Cappuzzo F., Janne P.A., Skokan M., Finocchiaro G., Rossi E., Ligorio C., Zucali P.A., Terracciano L., Toschi L., Roncalli M., Destro A., Incarbone M., Alloisio M., Santoro A., Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 2009, 20:298-304.
7. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., Mendel D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes invitro and exhibits cytoreductive antitumor activity invivo. Cancer Res. 2003, 63:7345-7355.
8. DiPaola R.S. To arrest or not to G2-M Cell-cycle arrest: commentary re: A. K. Tyagi etal., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res., 8: 3512-3519, 2002. Clin. Cancer Res. 2002, 8:3311-3314.
9. Eathiraj S., Palma R., Volckova E., Hirschi M., France D.S., Ashwell M.A., Chan T.C. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J.Biol. Chem. 2011, 286:20666-20676.
10. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
11. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G., Kwiatkowski D.J., Engelman J.A., Janne P.A. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
12. Fasolo A., Sessa C., Gianni L., Broggini M. Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Ann. Oncol. 2013, 24:14-20.
13. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12:89-103.
14. Goldman J.W., Laux I., Chai F., Savage R.E., Ferrari D., Garmey E.G., Just R.G., Rosen L.S. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012, 118:5903-5911.
15. Jordan M.A., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991, 51:2212-2222.
16. Katayama R., Aoyama A., Yamori T., Qi J., Oh-hara T., Song Y., Engelman J.A., Fujita N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013, 73:3087-3096.
17. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., Holcomb T., Pujara K., Stinson J., Fu L., Severin C., Rangell L., Schwall R., Amler L., Wickramasinghe D., Yauch R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006, 66:283-289.
18. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Janne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N.Engl. J. Med. 2010, 363:1693-1703.
19. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., Pan B.-S. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007, 67:2081-2088.
20. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., Richards W., Sugarbaker D., Husain A.N., Christensen J.G., Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005, 65:1479-1488.
21. Matsubara D., Ishikawa S., Oguni S., Aburatani H., Fukayama M., Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J.Thorac. Oncol. 2010, 5:1317-1324.
22. Munshi N., Jeay S., Li Y., Chen C.R., France D.S., Ashwell M.A., Hill J., Moussa M.M., Leggett D.S., Li C.J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 2010, 9:1544-1553.
23. Park S., Choi Y.L., Sung C.O., An J., Seo J., Ahn M.J., Ahn J.S., Park K., Shin Y.K., Erkin O.C., Song K., Kim J., Shim Y.M., Han J. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol. Histopathol. 2012, 27:197-207.
24. Peters S., Adjei A.A. MET: a promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012, 9:314-326.
25. Sadiq A.A., Salgia R. MET as a possible target for non-small-cell lung cancer. J.Clin. Oncol. 2013, 31:1089-1096.
26. Scagliotti G., Novello S., Ramlau R., Favaretto A., Barlesi F., Akerley W., Von Pawel J., Shuster D., Schwartz B., Sandler A.B. MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC) 2013, European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Abstract 3410.
27. Scagliotti G.V., Novello S., Schiller J.H., Hirsh V., Sequist L.V., Soria J.C., von Pawel J., Schwartz B., Von Roemeling R., Sandler A.B. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin. Lung Cancer 2012, 13:391-395.
28. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J.Clin. Oncol. 2005, 23:9408-9421.
29. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., Chen Y., Costa D.B., Gerber D.E., Orlov S., Ramlau R., Arthur S., Gorbachevsky I., Schwartz B., Schiller J.H. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J.Clin. Oncol. 2011, 29:3307-3315.
30. Shibata T., Uryu S., Kokubu A., Hosoda F., Ohki M., Sakiyama T., Matsuno Y., Tsuchiya R., Kanai Y., Kondo T., Imoto I., Inazawa J., Hirohashi S. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin. Cancer Res. 2005, 11:6177-6185.
31. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.G., Settleman J., Haber D.A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U S A 2006, 103:2316-2321.
32. Spigel D.R., Edelman M.J., Mok T., O'Byrne K.J., Paz-Ares L., Yu W., Rittweger K., Thurm H.C. The MetLUNG study: a randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2012 ASCO Ann. Meet. Proc. 2012, 30. and on behalf of the MetLUNG Phase III Study Group, TPS7616.
33. Spigel D.R., Ervin T.J., Ramlau R.A., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., Krzakowski M.J., Robinet G., Godbert B., Barlesi F., Govindan R., Patel T., Orlov S.V., Wertheim M.S., Yu W., Zha J., Yauch R.L., Patel P.H., Phan S.-C., Peterson A.C. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J.Clin. Oncol. 2013, 31:4105-4114.
34. Tanizaki J., Okamoto I., Okamoto K., Takezawa K., Kuwata K., Yamaguchi H., Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J.Thorac. Oncol. 2011, 6:1624-1631.
35. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.G., Engelman J.A., Janne P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
36. Yap T.A., Olmos D., Brunetto A.T., Tunariu N., Barriuso J., Riisnaes R., Pope L., Clark J., Futreal A., Germuska M., Collins D., deSouza N.M., Leach M.O., Savage R.E., Waghorne C., Chai F., Garmey E., Schwartz B., Kaye S.B., de Bono J.S. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J.Clin. Oncol. 2011, 29:1271-1279.
37. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., Beheshti J., Lee J.C., Naoki K., Richards W.G., Sugarbaker D., Chen F., Rubin M.A., Janne P.A., Girard L., Minna J., Christiani D., Li C., Sellers W.R., Meyerson M. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005, 65:5561-5570.
38. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., Engen J.R., Wong K.K., Eck M.J., Gray N.S., Janne P.A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.